Having been ISO 9001:2015 certified for several years, we’re delighted to be able to add ISO 13485:2016 certification to our achievements. We have long believed in the quality of our products and services, and we are delighted that our recent audit reflected this.
We want to thank all our customers for their patience over the last few months and we very much look forward to the future.
To see the certificate click here
We’re delighted to have been nominated in two categories at the Made in Wales Awards 2021. We’ve been nominated for awards in:
We’re really pleased with these nominations. Globally, it’s been a challenging 18 months yet, at Benson Viscometers, we’ve operated fully throughout without having to lay off or even furlough any staff. We’ve even recruited in that time and are continuing to hire new staff. We hope that this is all a reflection of the hard work and dedication of our staff and we’d like to take the opportunity to thank them for all of their commitment. We’d also like to extend our warmest thanks to our customers who themselves have had to deal with these extremely challenging times.
The awards are towards the end of October so fingers crossed!
The winner of the Bernie Benson Award 2021 was Daniel Gleghorn and the research team at Addenbrookes Hospital in Cambridge.
For the 2021 Award, nominations were invited for anyone who has achieved outstanding progression in clinical viscosity. Individuals were able to nominate colleagues or anyone else they know who had championed clinical viscosity testing, its uses and benefits.
We received several worthy nominations but one stood out amongst them all. The work done by Daniel Gleghorn and the research team at Addenbrookes Hospital was the clear winner. They’d undertaken a study into the link between plasma viscosity and the progression of COVID-19 in patients admitted to the hospital with the virus.
The research demonstrated a sensitive and original use of plasma viscosity in the risk stratification of patients with COVID‐19 infection. This research could change the way we manage the pandemic and help to quickly categorize patients with suspected symptoms of COVID‐19 into high or low disease complication risk groups. The research was published in the International Journal of Laboratory Hematology.
Daniel was presented with his prize by Bernie and Julie Benson, directors of Benson Viscometers. He received it on behalf of the research team at Addenbrookes on Friday 9th with Anthony Browne, MP for South Cambridgeshire, and Cllr Mark Ashton, Deputy Mayor for Cambridge, along with his wife Barbara, all present.
You can read all about the work and the award presentation here.
An article published recently in the MLO in the USA adds further evidence to the benefits of using plasma viscosity testing when managing patients suffering from COVID-19. It follows on from the study published by Addenbrookes Hospital in Cambridge earlier this year.
With the growing body of evidence for the use of plasma viscosity testing for managing COVID-19, now is the time to explore how our clinical viscometers can help healthcare professionals to better utilise their resources during the pandemic.
We are pleased to announce that the 2021 winner is Daniel Gleghorn from Addenbrookes Hospital in Cambridge. We were looking for nominations for individuals who have championed clinical viscosity testing and really taken it forward. Out of all the nominations we received, the stand-out person was Daniel who led the research team within the Cambridge University Hospital NHS Foundation in a study into the diagnostic value of plasma viscosity testing for patients with COVID-19.
The research demonstrated a sensitive and original use of plasma viscosity in the risk stratification of patients with COVID‐19 infection. This research could change the way we manage the pandemic and help to quickly categorize patients with suspected symptoms of COVID‐19 into high or low disease complication risk groups. The research was published in the International Journal of Laboratory Hematology.
We are looking forward to Daniel being able to accept his prize. With COVID restrictions still in place we’ve not been able to set a date but will arrange a presentation as soon as practical and safe to do so.
Well done Daniel!
For more information on Daniel’s research, and to see the paper, just click here
A paper published on April 4th 2021 in International Journal of Laboratory Hematology has shown the strongest evidence yet of the diagnostic potential of using plasma viscosity testing for patients with suspected COVID‐19.
The research, conducted by Dan Gleghorn et al. at Addenbrookes Hospital in Cambridge demonstrated a sensitive and original use of plasma viscosity (PV) in the risk stratification of patients with COVID‐19 infection. This research could change the way we manage the pandemic and help to quickly categorize patients with suspected symptoms of COVID‐19 into high or low disease complication risk groups.
The research found that 171 COVID-19 positive patients admitted to the hospital in April and May 2020 had a mean PV of 2.00mPas. This was compared to a mean PV of 1.62mPas in 224 patients who were tested for COVID-19 and found to be negative. This is a significant increase between those testing positive and negative. In fact, the research found that a plasma viscosity result above 1.83mPas is shown to have good correlation with disease progression.
This research could ease the burden on health services all over the world. The measurement of plasma viscosity is a cheap and reliable test already available in many haematology laboratories.
You can see the full research paper here:
https://onlinelibrary.wiley.com/doi/full/10.1111/ijlh.13532
Nominate someone in your lab who has achieved outstanding progression in Clinical Viscosity for their chance to win a Lenovo V15 Laptop!
Closing Date: 5th March 2021.
Link to the paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31209-5/fulltext
Award rules
Benson Viscometers is developing a novel device that can determine the clotting profile of a blood samples. Furthermore, as this introduction explains, the company also aims to develop the point-of-care capabilities of this device, and also disposables for specialist testing.
The diagnostic and prognostic value of measuring plasma viscosity has been highlighted recently in patients suspected or confirmed as having COVID-19; however, its use in other area of UK medical practice has gained clinical acceptance and important over the past seven decades since its first description in literature.
Benson Viscometers has been shortlisted in the “Made In Wales Awards” under the following categories, Export Award, Manufacturing Innovation Award, and the Medical, Life Sciences and Health Care Award.
For more information please click on the link below:
https://www.insidermedia.com/news/wales/made-in-wales-shortlists-revealed
